Christine L Talarico
Overview
Explore the profile of Christine L Talarico including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jaeger H, Overton E, Richmond G, Rizzardini G, Andrade-Villanueva J, Mngqibisa R, et al.
Lancet HIV
. 2021 Oct;
8(11):e679-e689.
PMID: 34648734
Background: Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting...
2.
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, et al.
AIDS
. 2021 Jul;
36(2):185-194.
PMID: 34261093
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48...
3.
Cutrell A, Schapiro J, Perno C, Kuritzkes D, Quercia R, Patel P, et al.
AIDS
. 2021 Mar;
35(9):1333-1342.
PMID: 33730748
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with...
4.
Rizzardini G, Overton E, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, et al.
J Acquir Immune Defic Syndr
. 2020 Nov;
85(4):498-506.
PMID: 33136751
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies....
5.
Swindells S, Andrade-Villanueva J, Richmond G, Rizzardini G, Baumgarten A, Masia M, et al.
N Engl J Med
. 2020 Mar;
382(12):1112-1123.
PMID: 32130809
Background: Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. Methods: In this phase 3, open-label, multicenter, noninferiority trial...
6.
DeJesus E, Harward S, Jewell R, Johnson M, Dumont E, Wilches V, et al.
Clin Infect Dis
. 2019 Nov;
71(5):1255-1262.
PMID: 31769793
Background: GSK2838232 is a second-generation, potent, small-molecule, oral human immunodeficiency virus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhancer. Methods: The phase 2a, proof-of-concept study was...
7.
Dooley K, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al.
Clin Infect Dis
. 2019 Mar;
70(4):549-556.
PMID: 30918967
Background: The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of...
8.
Baughman T, Talarico C, Soglia J
Rapid Commun Mass Spectrom
. 2009 Jun;
23(14):2146-50.
PMID: 19517456
Propranolol is a widely used quality control and validation compound for liver microsome and hepatocyte metabolism studies. A multitude of literature reports describing the identification of propranolol metabolites exists today....
9.
Selleseth D, Talarico C, Miller T, Lutz M, Biron K, Harvey R
Antimicrob Agents Chemother
. 2003 Mar;
47(4):1468-71.
PMID: 12654696
Inhibition of human cytomegalovirus (HCMV) by 1263W94 was additive dosewise in combination with ganciclovir, acyclovir, and foscarnet. None of the commonly used anti-human immunodeficiency virus agents antagonized the inhibition of...
10.
Lalezari J, Aberg J, Wang L, Wire M, Miner R, Snowden W, et al.
Antimicrob Agents Chemother
. 2002 Aug;
46(9):2969-76.
PMID: 12183255
1263W94 [maribavir; 5,6-dichloro-2-(isopropylamino)-1,beta-L-ribofuranosyl-1-H-benzimidazole] is a novel benzimidazole compound for treatment of human cytomegalovirus (HCMV) infection and disease, with potent in vitro activity against HCMV and good oral bioavailability. A phase...